Kailera Therapeutics Inc. shares surged 63% after the clinical-stage biotechnology company focused on obesity raised $625 ...

From side effects to treatment timelines, here's what she says most people misunderstand about these medications.

A group of global experts is proposing a new way to define and diagnose obesity, reducing the emphasis on the controversial ...

Kailera Therapeutics Inc., a clinical-stage biotechnology company focused on obesity, raised $625 million in an upsized ...

New research to be presented at the European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12–15 May) shows that living ...

The FDA is asking Eli Lilly to submit cardiovascular and liver safety data from an ongoing Phase 3 trial of Foundayo by July.

Incretin-based obesity medications may result in higher muscle-related loss vs. other weight loss strategies, according to ...

Viking's candidate is part of the GLP-1 class of drugs, which interact with hormonal pathways controlling appetite and blood ...

New research reveals that obesity affects men and women in surprisingly different ways. Men are more likely to develop harmful abdominal fat and signs of liver stress, while women show higher ...

TF: GLP-1s were first discovered as therapies for type 2 diabetes, and their weight-loss properties were practically a bonus.

Louisiana lawmakers debated a bill that would require Medicaid to cover FDA-approved weight-loss medications for its ...